ADMETRx
This article was originally published in Start Up
Executive Summary
ADMETRx is building new and improved ADME tools. The technology, a mix of wet lab analysis and computer modeling, attempts to move beyond the go/no go decisions typical of ADME.Instead the company offers clients a ranking of a drugs being tested based on the individual properties being tested.
You may also be interested in...
The Buzz around Exploratory INDs
The impact of FDA's Final Guidance on the use of Exploratory IND Studies could be profound for firms ranging from start-ups anticipating their first human drug tests to Big Pharmas with thousands of leads to manage and prioritize. Some service organizations may also benefit from the new regs, which may prompt an early clinical assessment of increasing numbers of compounds.
Of Mice and Men: Predictive Toxicology
Current in vivo and in vitro models can't keep up with the demand for the safety assessment of large numbers of compounds emerging from high-throughput strategies. Pharmaceutical companies and start-ups are therefore building new systems that they hope will be capable of predicting the toxicity liabilities of new compounds. Cheminformatics can help week out toxic compounds at the lead selection and optimization stage; toxicogenomics may provide a toxicity diagnostic capability at all stages of drug development. For both toxicology approaches, there is not yet enough high quality data to build predictive models. Toxicology-focused cheminformatics programs attempt to consolidate data from hitherto untapped sources; toxicogenomics companies are engaged in the fussy and expensive process of manufacturing data from scratch and validating them with biological experiments.
The Value Lab: Moving Value-Based Health Care From Theory To Practice
Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.